Journal
INTERNAL MEDICINE JOURNAL
Volume 50, Issue 7, Pages 798-804Publisher
WILEY
DOI: 10.1111/imj.14889
Keywords
COVID-19; SARS-CoV-2; inflammatory bowel disease; Crohn disease; ulcerative colitis; immunosuppression
Categories
Ask authors/readers for more resources
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there are insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease (IBD) patients in the context of the COVID-19 pandemic in the Australasian setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available